Gregory S. Calip, PharmD, MPH, PhD^1,2,3*, Wan-Ju Lee, MS^1,2*, Todd A. Lee, PharmD, PhD^1,2*, Glen T. Schumock, PharmD, MBA, PhD^1,2* and Brian C.-H. Chiu, PhD⁴

¹Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL
²Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL
³Population Health, Behavior and Outcomes Program, University of Illinois Cancer Center, Chicago, IL
⁴Department of Public Health Sciences, The University of Chicago, Chicago, IL

Bruno Paiva, PhD^1*, Maria-Victoria Mateos², Luis Ignacio Sánchez-Abarca^3*, Maria Belen Vidriales, MD, PhD^4*, Lucia Lopez-Corral, M.D.^5*, Luis A Corchete^5*, Miguel T Hernandez^6*, Joan Bargay, MD, PhD^7*, Felipe De Arriba^8*, Javier De La Rubia^9*, Ana Isabel Teruel, MD^10*, Pilar Giraldo, MD, PhD¹¹, Laura Rosiñol, MD PhD^12*, Felipe Prosper, MD¹³, Albert Oriol, MD PhD^14*, Jose Mariano Hernandez, MD^15*, Graça Esteves^16*, Fernando Leal da Costa^17*, Juan Jose Lahuerta^18*, Joan Blade, MD PhD¹², Jose A. Perez-Simon, M.D., PhD¹⁹ and Jesus San Miguel, MD PhD^20*

¹Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
²Hematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain
³Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain
⁴Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
⁵Hospital Universitario de Salamanca, Salamanca, Spain
⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
⁷Hospital Son Llàtzer, Palma de Mallorca, Spain
⁸Hematology and Clinical Oncology Unit, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain
⁹H.U.P. La Fe, Valencia, Spain
¹⁰Hospital Clinico de Valencia, Valencia, Spain
¹¹Hematology Research Center, Moscow, Russia
¹²Hospital Clinic de Barcelona, Barcelona, Spain
¹³Clinica Universidad de Navarra, Pamplona, Spain
¹⁴Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
¹⁵Hospital General de Segovia, Segovia, Spain
¹⁶Hospital de Santa María, Lisboa, Portugal
¹⁷Instituto Portugués de Oncología, Lisboa, Portugal
¹⁸Hospital 12 de Octubre, Madrid, Spain
¹⁹Dept. of Hematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
²⁰Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain

Tatiana Prokaeva^1*, Brian Spencer^1*, Fangui Sun^2*, Nathaniel McConnell^3*, Richard M O'hara^4*, David C Seldin^5*, Lawreen Connors^1* and Vaishali Sanchorawala⁵

¹Boston University School of Medicine, Boston, MA
²Boston University School of Public Health, Boston, MA
³The Binding Site Group Ltd., Birmingham, United Kingdom
⁴The Binding Site, Inc., San Diego, CA
⁵Boston Medical Center, Boston, MA

Niina Ueno, MD^*, Shikiko Ueno, MD, PhD, Shinya Endo, MD^*, Nao Nishimura, MD^*, Hiro Tatetsu, MD, PhD, Shinya Hirata, MD, PhD^*, Hiroaki Mitsuya, MD, PhD^* and Yutaka Okuno, MD, PhD

Department of Hematology, Kumamoto University Graduate School of Medicine, Kumamoto, Japan

Valentine Richez Jr., MD^1*, Frederic Luciano, PHD^2*, Amine Hamouda, PHD^2*, Alexandre Puissant^3*, Guillaume Robert, PhD^4*, Arnaud Jacquel, PhD^5*, Thomas Cluzeau, MD, PhD^6*, Kenneth C Anderson, MD⁷, Jean-Gabriel Fuzibet, MD^8* and Patrick Auberger, PhD^4*

¹Hospital, NICE, France
²Inserm U1065, Nice, France
³Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA
⁴Inserm U1065, Nice, France, Nice, France
⁵Inserm U1065, Nice, France, Nice Cedex 03, France
⁶Hematology, Saint Louis Hospital, Paris, France
⁷The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Hospital, Nice, France

Denise Toscani, PhD^1*, Marina Bolzoni, PhD^1*, Federica Costa^1*, Valeria Quarona^2*, Valentina Marchica^1*, Cristina Mancini, MD^3*, Eugenia Martella, MD^3*, Sabrina Bonomini^4*, Paola Storti, PhD^1*, Antonella Chillemi, PhD^2*, Fabrizio Accardi, MD^4*, Benedetta Dalla Palma, MD^4*, Luisa Craviotto, MD^1,4*, Fabio Malavasi, MD^5*, Franco Aversa, MD^1,4* and Nicola Giuliani, MD, PhD^1,4

¹Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
²Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino, Italy
³Pathology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
⁴Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
⁵Laboratory of Immunogenetics, University of Torino, Torino, Italy

Ming Han, BSc.^1*, Alli Murugesan, MSc, PhD^1*, Nizar J Bahlis, MD², Kevin Song³, Darrell White, MD, MSc, FRCPC, FACP⁴, Christine Chen, MD⁵, Matthew D. Seftel, MBChB, FRCP(C), MRCP⁵, Kang Howsen-Jan, MD^6*, Donna Reece⁷, Keith Stewart, MD⁸, Yagang Xie, MD, PhD, FCCMG^9*, Annette E Hay, MB ChB¹⁰, Lois Shepherd, MD¹¹, Bingshu E Chen, PhD^11*, Marina Djurfeldt, MSc.^11* and Tony Reiman, MD¹²

¹Biology, University of New Brunswick, Saint John, NB, Canada
²University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada
³Hematology, Vancouver General Hospital, Vancouver, BC, Canada
⁴Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, NS, Canada
⁵Princess Margaret Hospital, Toronto, ON, Canada
⁶London Health Sciences Centre, London, ON, Canada
⁷Princess Margaret Cancer Centre, Toronto, ON, Canada
⁸Mayo Clinic Arizona, Scottsdale, AZ
⁹Laboratory Medicine, Saint John Regional Hospital, Saint John, NB, Canada
¹⁰Department of Internal Medicine, Queen's University, Kingston, ON, Canada
¹¹NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada
¹²Dept of Oncology, Saint John Regional Hospital, University of New Brunswick, Saint John, NB, Canada

Marina Martello, PhD^1*, Daniel Remondini, PhD^2*, Enrica Borsi, PhD^1*, Mauro Procacci^1*, Barbara Santacroce^1*, Annalisa Pezzi, PhD^1*, Angela Flores Dico^1*, Elena Zamagni^1*, Paola Tacchetti, MD^1*, Lucia Pantani, MD^1*, Giulia Marzocchi, PhD^1*, Giovanni Martinelli, MD, PhD³, Michele Cavo^1* and Carolina Terragna, PhD^1*

¹DIMES - Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology, University of Bologna, Bologna, Italy
²Department of Physics and Astronomy, University of Bologna, Bologna, Italy
³Bologna University School of Medicine, Bologna, Italy

Lucia Lopez-Anglada, MD PhD^1,2*, Cecilia Cueto-Felgueroso^3*, Maria-Victoria Mateos⁴, Laura Rosiñol, MD PhD^5*, Albert Oriol, MD PhD^6*, Ana Isabel Teruel, MD^7*, Ana Lopez de la Guia, MD^8*, Luis Palomera, MD PhD^9*, Felipe de Arriba, MD PhD^10*, Jose Mariano Hernandez, MD^11*, Miquel Granell, MD^12*, Francisco Javier Peñalver, MD^13*, Ramon Garcia-Sanz, MD PhD^4,14*, Juan Besalduch, MD PhD¹⁵, Yolanda Gonzalez, MD^16*, Rafael Martinez, MD PhD^17*, Miguel Teodoro Hernandez, MD PhD^18*, Norma C Gutierrez^4,14*, Paloma Puerta, MD^3*, Joan Blade, MD PhD^5,19, Jesús San Miguel, MD PhD^20*, Juan José Lahuerta, MD PhD^1,2* and Joaquin Martinez Lopez, MD PhD^1,2*

¹Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
²Hospital Universitario 12 de Octubre, Instituto Investigacion Biomedica I+12, Madrid, Spain
³Clinical Biochemistry, Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
⁵Hospital Clinic de Barcelona, Barcelona, Spain
⁶Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
⁷Hospital Clinico de Valencia, Valencia, Spain
⁸Haematology, Hospital Universitario La Paz, Madrid, Spain
⁹Department of Hematology, Hospital Universitario Lozano Blesa, Zaragoza, Spain
¹⁰Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonación. Universidad de Murcia. IMIB, MURCIA, Spain
¹¹Hospital General de Segovia, Segovia, Spain
¹²Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Barcelona, Spain
¹³Hospital Universitario Fundación Alcorcon, Madrid, Spain
¹⁴Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
¹⁵Hematology, University Hospital Son Espases, Palma, Spain
¹⁶Haematology, Institut d’Oncologia Dr Josep Trueta de Girona, Girona, Spain
¹⁷Hospital Universitario San Carlos, Madrid, Spain
¹⁸Hospital Univeritario de Canarias, Tenerife, Spain
¹⁹Department of Hematology, Amyloidosis and Myeloma Unit. Hospital Clínic, IDIBAPS, Barcelona, Spain
²⁰Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain

Paula Arana^1*, Bruno Paiva, PhD^2*, Maria Belen Vidriales, MD, PhD^3*, Juan A Flores-Montero, MD^4*, Noemi Puig, MD, PhD^3*, Teresa Cedena^5*, Lourdes Cordon^6*, Joaquin Martinez-López, MD.PhD^7*, Enrique M. Ocio, MD, PhD^8*, Miguel T Hernandez^9*, Ana Isabel Teruel, MD^10*, Mercedes Gironella^11*, M Asuncion Echeveste^12*, Laura Rosiñol, MD PhD^13*, Joan Blade, MD PhD¹³, Juan Jose Lahuerta^14*, Jacques J.M. van Dongen¹⁵, Alberto Orfao, MD, PhD¹⁶, Maria-Victoria Mateos¹⁷ and Jesus San Miguel, MD, PhD¹⁸

¹Clinica Universidad de Navarra, Pamplona, Spain
²Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
³Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
⁴Servicio General de Citometría (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain
⁵Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
⁶Hospital Universitario La Fe, Valencia, Spain
⁷Hematology, Hospital 12 de Octubre, Madrid, Spain
⁸University Hospital of Salamanca, Salamanca, Spain
⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
¹⁰Hospital Clinico de Valencia, Valencia, Spain
¹¹Hospital Universitari Vall dHebron, Barcelona, Spain
¹²Hospital Universitario Donostia, San Sebastian, Spain
¹³Hospital Clinic de Barcelona, Barcelona, Spain
¹⁴Hospital 12 de Octubre, Madrid, Spain
¹⁵Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
¹⁶Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC), Servicio General de Citometría, Universidad de Salamanca, Salamanca, Spain
¹⁷Hematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain
¹⁸Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain

Jennifer Postelnek, BA^1*, James Sheridan^2*, Steve Keller^2*, Tatiana Pazina, MS, BS^3*, Jennifer Sheng^1*, Valerie Poulart^4* and Michael Robbins, BS^1*

¹Bristol-Myers Squibb, Princeton, NJ
²AbbVie Biotherapeutics, Inc., Redwood City, CA
³Fox Chase Cancer Center, Philadelphia, PA
⁴Bristol-Myers Squibb, Braine-l'Alleud, Belgium

Angelo Belotti, MD^1*, Michele Malagola², Claudia Crippa, MD^3*, Ilaria Prezioso^4*, Francesca Schieppati^5*, Rossella Ribolla^6*, Vincenza Orlando^7*, Domenico Russo⁸ and Giuseppe Rossi, MD⁹

¹Division of Hematology, Spedali Civili,, Brescia, Italy
²Chair of Hematology, Unit of Blood Diseases and Stem Cell Transplantation , University of Brescia, Brescia, Italy
³Hematology, Spedali Civili, Brescia, Italy
⁴University of Brescia, Brescia, Italy
⁵Division of Hematology, A.O. Spedali Civili of Brescia, Brescia, Italy
⁶Division of Hematology, Spedali Civili, Brescia, Italy
⁷Hematology, Spedali Civili di Brescia, Brescia, Italy
⁸Chair of Hematology, University of Brescia, Brescia, Italy
⁹Department of Hematology, Spedali Civili di Brescia, Brescia, Italy

Manisha Bhutani, MD¹, David Foureau, Ph.D.^2*, Tammy Cogdill, NP^1*, Kyle Madden, BS^1*, Qing Zhang, Ph.D.³, Sarah A Baxter, PhD^4*, Lawrence J Druhan, PhD⁴, Nilanjan Ghosh, MD, PhD⁵, Belinda R Avalos, MD⁴, Edward A. Copelan, MD⁶ and Saad Z Usmani, MD, FACP⁷

¹Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC
²Immnune Monitoring Core Laboratory Cannon Research Center/Carolinas Healthcare System, Charlotte, NC
³Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC
⁴Department of Hematologic Oncology and Blood Disorders, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC
⁵Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC
⁶Carolinas Health Care, Levine Cancer Center, Charlotte, NC
⁷Levine Cancer Institute/Carolinas Healthcare System,, Charlotte, NC

Mark van Duin, PhD^1*, Rowan Kuiper, BSc^2*, Martin van Vliet, PhD^2*, Annemiek Broijl, MD, PhD^1*, Leonie de Best, MSc^2*, Erik van Beers, PhD^2*, Bronno Van Der Holt, PhD^3*, Heleen Visser-Wisselaar, PhD^4*, Lizanne Bosman, BSc^2*, Belinda Dumee, BSc^2*, Fanni van den Bosch, BSc^2*, Michael Vermeulen, BSc^1*, Jasper Koenders, BSc^1*, Marian Stevens-Kroef, PhD^5*, Anders Waage, MD, PhD⁶, Sonja Zweegman, MD, PhD⁷ and Pieter Sonneveld, MD, PhD¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²SkylineDx, Rotterdam, Netherlands
³HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, Netherlands
⁴HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, Netherlands
⁵Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands
⁶Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
⁷Department of Hematology, VUMC, Amsterdam, Netherlands

Ju Bai^1*, Aili He^1*, Wanggang Zhang^1*, Yun Yang^1*, Jianli Wang^1*, Pengyu Zhang^1*, Yuandong Feng^1*, Lei Zhang^2*, Hongli Chen^1*, Xiaman Wang^1*, Xiaoru Lei^1*, Ying Shen^1* and Lingjuan Huang^1*

¹Department of Hematology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China
²Department of Clinical Lab, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China

Isabel JF Hofman^1,2*, Mark van Duin, PhD^3*, George Mulligan, PhD^4*, Ellen Geerdens^2,5*, Emanuela Garelli^6*, Cecilia Mancini^7*, Heidi Lemmens^8*, Michel Delforge⁹, Peter Vandenberghe, MD PhD¹⁰, Iwona Wlodarska⁵, Anna Aspesi^11*, Lucienne Michaux^5,8*, Pieter Sonneveld, MD, PhD¹² and Kim De Keersmaecker^1,2

¹Department of Oncology, KU Leuven, Leuven, Belgium
²Center for the Biology of Disease, VIB, Leuven, Belgium
³Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁴Takeda Pharmaceuticals, Inc., Cambridge, MA
⁵Center for Human Genetics, KU Leuven, Leuven, Belgium
⁶Dipartimento Scienze della Sanità Pubblica e Pediatriche, Iniv. Torino, Torino, Italy
⁷Dipartimento di Scienze Mediche, Univ.Torino, Torino, Italy
⁸University Hospitals Leuven, Leuven, Belgium
⁹University Hospital Leuven, Leuven, Belgium
¹⁰Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
¹¹Department of Health Sciences, Universita' del Piemonte Orientale, Novara, Italy
¹²Department of Hematology, Erasmus MC, Rotterdam, Netherlands

Martin van Vliet, PhD^1*, Joske Ubels, MSc^1*, Leonie de Best, MSc^1*, Erik van Beers, PhD^1* and Pieter Sonneveld, MD, PhD²

¹SkylineDx, Rotterdam, Netherlands
²Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Cristina Jimenez, BsC^1*, Isabel Prieto-Conde, BsC^2*, María García-Álvarez, BsC^2*, María Carmen Chillón, BsC, PhD^2*, Aránzazu García-Mateo, MD^3*, Fernando Escalante, MD^4*, Tomás González-López, MD^5*, Pilar Giraldo, MD, PhD⁶, Alfonso Garcia de Coca, MD, PhD^7*, Miguel Alcoceba^8*, Ana Balanzategui, BsC^2*, Maria Eugenia Sarasquete, BsC, PhD^2*, Luis Alberto Marin, BsC, PhD^2*, Maria-Victoria Mateos⁹, Enrique M Ocio^10*, Marcos González, MD, PhD^8*, Jesus F San Miguel, MD, PhD¹¹, Ramon Garcia-Sanz, MD, PhD^12* and Noemi Puig, MD, PhD^13*

¹Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
²Hematology Department, University Hospital of Salamanca, Salamanca, Spain
³Hematology Department, Hospital General de Segovia, Segovia, Spain
⁴Hematology Department, Complejo Hospitalario de León, León, Spain
⁵Hematology Department, Complejo Hospitalario de Burgos, Burgos, Spain
⁶Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza, Spain
⁷Hospital Clínico Universitario de Valladolid, Valladolid, Spain
⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain
⁹Hematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain
¹⁰Complejo Asistencial Universitario de Salamanca (IBSAL) y Centro de Investigación del Cáncer (IBMCC-CSIC). Universidad de Salamanca, Salamanca, Spain
¹¹Hematologia, Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC), Salamanca, Spain
¹²Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
¹³Instituto Biosanitario de Salamanca (IBSAL) and Cancer Research Centre (Instituto de Biología Molecular y Celular del Cáncer; CSIC-USAL), Salamanca, Spain

Beatriz Sanchez-Vega^1*, Santiago Barrio^2*, Yanira Ruiz^3*, Ramon Garcia-Sanz, MD, PhD^4*, Bruno Paiva, PhD^5*, Carlos Marin^3*, Roberto Maldonado^3*, Inmaculada Rapado^1*, Jose Cervera, MD^6*, Rosa M. Ayala, MD, PhD⁷, Teresa Cedena^8*, Cristina Jimenez, BsC^4*, Miguel T Hernandez^9*, Rafael Martinez, MD^10*, Enrique M Ocio^11*, M Asuncion Echeveste^12*, Laura Rosinol^13*, Joan Blade¹³, Maria-Victoria Mateos⁴, Jesus San Miguel, MD PhD^14*, Juan Jose Lahuerta, MD, PhD^7* and Joaquin Martinez Lopez, MD PhD^7*

¹Hospital-12-de-Octubre, Madrid, Spain
²Mayo Clinic, Scottsdale, AZ
³Traslational Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
⁵Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
⁶Hematology, Hospital La Fe, Valencia, Spain
⁷Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
⁸Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
¹⁰Hospital Clinico, Madrid, Spain
¹¹Centro de Investigación del Cancer Universidad de Salamanca-CSIC, Salamanca, Spain
¹²Hospital Universitario Donostia, San Sebastian, Spain
¹³Hematology, Hospital Clinic i Provincial, Barcelona, Spain
¹⁴Clinical Universidad de Navarra, Pamplona, Spain

Zarko Manojlovic, PhD^1*, Austin Christofferson^1*, Christophe Legendre, PhD^1*, Gill Spreyer, PhD^1*, Seungchan Kim, PhD^1*, Winnie Liang, PhD^1*, George Mulligan, PhD^2*, Pamela G. Kidd, MD³, Scott Jewell, PhD^4*, Mary Derome, MS^5*, Jen Troups^5*, Daniel Auclair, PhD^5*, Sagar Lonial, MD^6,7,8,9, David Craig, PhD^1*, Jonathan J Keats, Ph.D.¹ and John David Carpten, PhD^1*

¹Translational Genomics Research Institute, Phoenix, AZ
²Takeda Pharmaceuticals, Inc., Cambridge, MA
³Spectrum Health, Grand Rapids, MI
⁴Van Andel Research Institute, Grand Rapids, MI
⁵Multiple Myeloma Research Foundation, Norwalk, CT
⁶Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA
⁷Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
⁸Winship Cancer Institute, Emory University, Atlanta, GA
⁹Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

David R Fooksman, PhD^1*, Amitabha Mazumder, M.D.² and Mark McCarron, PhD^1*

¹Albert Einstein College of Medicine, Bronx, NY
²NYU School of Medicine, NYU Cancer Center, New York, NY

Jeremy Ross, PhD^1*, Martine Amiot, PhD^2*, Brenda Chyla, PhD^1*, Lisa Roberts-Rapp^1*, Rasna Goswami^1*, Sun Yan^1*, Xin Huang^1*, Anahita Bhathena^1*, Sari Heitner Enschede, MD^1*, Paulo Maciag, MD^1*, Rod A. Humerickhouse, MD, PhD¹ and Evelyn McKeegan^1*

¹AbbVie Inc., North Chicago, IL
²INSERM UMR-892, CHU, Nantes, France

Rosalie G Waller, BS^1,2, Karen Curtin, PhD^3*, Djordje Atanackovic, MD², Guido J Tricot, MD, PhD⁴, Steven M Lipkin, MD, PhD^5* and Nicola J Camp, PhD^1,2*

¹Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT
²Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, UT
³Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
⁴Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
⁵Weill Cornell Medical College, New York, NY

Jesus Delgado-Calle, PhD^1,2, Judith Anderson^3*, Meloney D. Cregor^4*, Nadia Carlesso, MD, PhD⁵, Khalid S. Mohammad, MD, PhD^6*, Lilian I. Plotkin, PhD^4*, Teresita M. Bellido, PhD^2,7* and G. David Roodman, MD, PhD^2,8

¹Department of Anatomy and Cell Biology, Indiana Univeristy School of Medicine, Indianapolis, IN
²Roudebush Veterans Administration Medical Center, Indianapolis
³Department of Medicine/Hematology and Oncology, Indiana Universisty, Indianapolis
⁴Department of Anatomy and Cell Biology, Indiana Univetrsity School of Medicine, Indianapolis
⁵Indiana University, Wells Center for Pediatric Research, Indianapolis, IN
⁶Department of Medicine, Division of Endocrinology, Indiana Univetrsity School of Medicine, Indianapolis
⁷Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN
⁸Department of Medicine/Hematology and Oncology, Indiana University, Indianapolis, IN

Pilar De La Puente, PhD¹, Barbara Muz, PhD, MSc¹, Feda Azab, BPharm^1*, Micah John Luderer, BS, MS¹, Jack L. Arbiser, M.D., Ph.D.^2* and Abdel Kareem Azab, BPharm, PhD¹

¹Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO
²Department of Dermatology, Emory University School of Medicine, Atlanta, GA

Carolina Schinke, MD^1*, Shayu Deshpande, PhD^1*, Alan Mitchell^2*, Malek Faham^3*, Purvi Patel^1*, Sharmilan Thanendrarajan, MD¹, Meera Mohan^1*, Pankaj Mathur^1*, Aasiya Matin^1*, Muthukumar Radhakrishnan^1*, Ruslana Tytarenko^1*, Owen W Stephens, PhD^1*, Frits van Rhee, MD, PhD¹, Maurizio Zangari, MD¹, Yogesh Jethava, MD^1*, Nathan Petty, MS^1*, Daisy V. Alapat, MD⁴, Sarah K. Johnson, PhD¹, Joshua Epstein, DSc¹, Bart Barlogie, MD, PhD¹, Faith E Davies, MD¹, Christoph Heuck, MD¹, Antje Hoering^2*, Niels Weinhold, PhD^1* and Gareth J Morgan, MD PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Cancer Research and Biostatistics, Seattle, WA
³Adaptive Biotech, san francisco, CA
⁴Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR

Sajjad Hussain, PhD^1*, Tibor Bedekovics, PhD^1*, Marta Chesi, PhD², Leif Bergsagel, MD, PhD² and Paul J. Galardy, MD¹

¹Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN
²Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ

Martin F Kaiser, MD^1,2*, Eileen Mary Boyle, MD, PhD^3,4*, Brian A Walker, PhD⁵, Dil B Begum^4*, Paula Proszek^5*, David C Johnson, PhD^4*, Charlotte Pawlyn, MB BChir^1,2*, John R Jones, MD^1,2*, Suvi Savola, PhD^6*, Roger G Owen⁷, Mark T Drayson, MD, PhD^8*, David A Cairns^9*, Gordon Cook, MD, PhD¹⁰, Walter M Gregory^9*, Richard S Houlston, MD PhD FRCP^11*, Faith E Davies, MD^1,12, Graham H Jackson, MD¹³ and Gareth J Morgan, MD, PhD^1,12

¹The Institute of Cancer Research, London, United Kingdom
²Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
³CHRU Lille, Maladies du Sang, Hopital Claude Huriez, Lille, France
⁴Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
⁵Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom
⁶MRC-Holland, Amsterdam, Netherlands
⁷United Leeds Teaching Hospitals, Leeds, United Kingdom
⁸Clinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom
⁹Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
¹⁰University of Leeds, Leeds, United Kingdom
¹¹Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
¹²Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
¹³Department of Haematology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Erming Tian, PhD¹, Joshua Epstein, DSc¹, Pingping Qu, PhD^2*, Christoph Heuck, MD¹, Frits van Rhee, MD, PhD¹, Maurizio Zangari, MD¹, Antje Hoering^2*, Jeffery Sawyer^3*, Bart Barlogie, MD, PhD¹ and Gareth J Morgan, MD PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Cancer Research and Biostatistics, Seattle, WA
³Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR

Martin F Kaiser, MD^1,2*, Eileen Mary Boyle, MD, PhD^3,4*, Brian A Walker, PhD⁵, Dil B Begum^4*, Paula Proszek^5*, David C Johnson, PhD^4*, Charlotte Pawlyn, MB BChir^1,2*, John R Jones, MD^1,2*, Suvi Savola, PhD^6*, Roger G Owen⁷, Mark T Drayson, MD, PhD^8*, David A Cairns^9*, Gordon Cook, MD, PhD¹⁰, Walter M Gregory^9*, Richard S Houlston, MD PhD FRCP^11*, Faith E Davies, MD^1,12, Graham H Jackson, MD¹³ and Gareth J Morgan, MD, PhD^1,12

¹The Institute of Cancer Research, London, United Kingdom
²Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
³CHRU Lille, Maladies du Sang, Hopital Claude Huriez, Lille, France
⁴Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
⁵Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom
⁶MRC-Holland, Amsterdam, Netherlands
⁷United Leeds Teaching Hospitals, Leeds, United Kingdom
⁸Clinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom
⁹Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
¹⁰University of Leeds, Leeds, United Kingdom
¹¹Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
¹²Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
¹³Department of Haematology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Davine Hofste op Bruinink, MD, MSc^1*, K. Martin Kortüm, MD^2*, Mark van Duin, PhD^1*, Mathijs A. Sanders, PhD^1*, Remco Hoogenboezem, MSc^1*, Michael Vermeulen, BSc^1*, Laura Bruins^2*, Jonathan Ahmann^2*, Annemiek Broijl, MD, PhD^1*, Sonja Zweegman, MD, PhD³, Esteban Braggio, PhD², Bronno van der Holt, PhD^4*, A. Keith Stewart, MD, PhD² and Pieter Sonneveld, MD, PhD¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
³Department of Hematology, VUMC, Amsterdam, Netherlands
⁴HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, Netherlands

Barbara Muz, PhD, MSc¹, Feda Azab, BPharm^2*, Pilar De La Puente, PhD¹, Justin King^3*, Micah John Luderer, BS, MS¹, Ravi Vij, MD, MBA⁴ and Abdel Kareem Azab, BPharm, PhD¹

¹Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO
²Washington University In St. Louis, Saint Louis, MO
³Washington Univeristy in St Louis, Saint Louis, MO
⁴Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO

Dominik Dytfeld, MD, PhD^1*, Magdalena Luczak, PhD^2*, Anna Przybylowicz-Chalecka, Msc^3*, Blazej Ratajczak, MSc^3*, Adam Nowicki, MD^3*, Joanna Czerwinska-Rybak, MSc^3*, Monika Joks, MD, PhD^3*, Tomasz Szczepaniak, MD, PhD^3*, Bochenek Maciej^3*, Andrzej Jakubowiak, MD, PhD⁴ and Mieczyslaw Komarnicki, MD, PhD⁵

¹Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences in Poznan, Poland, Poznan, Poland
²Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznan, Poland, Poznan, Poland
³University of Medical Sciences in Poznan, Poland, Poznan, Poland
⁴University of Chicago Medical Center, Chicago, IL
⁵Department of Hematology, Poznan University of Medical Sciences, Poznan, Poland

Silvia Gimondi^1*, Alessandra Cavanè^2*, Antonio Vendramin^1*, Biancon Giulia^2*, Anisa Bermema^2*, Vittorio Montefusco^2*, Paolo Corradini³ and Cristiana Carniti^1*

¹Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milan, Italy
²Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
³Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Rachel E Piddock, BSc^1*, Amina M Abdul-Aziz, MSc.^1*, Martin J Auger, MB ChB, MD^2*, Kristian M Bowles, MB BS, PhD^1,2 and Stuart A Rushworth, PhD, BSc^1*

¹Norwich Medical School, University of East Anglia, Norwich, United Kingdom
²Department of Haematology, Norfolk and Norwich University Hospital, Norwich, United Kingdom

Mehmet K Samur, Ph.D^1,2*, Annamaria Gulla, MD^3,4*, Alice Cleynen, PhD^1*, Florence Magrangeas^5*, Stephane Minvielle^5*, Kenneth C Anderson⁶, Giovanni Parmigiani, PhD^1*, Hervé Avet-Loiseau, MD^7* and Nikhil C. Munshi, MD²

¹Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
²LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Salvatore Venuta Campus, Magna Graecia University, Catanzaro, Italy
⁴Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France
⁶The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé, Toulouse, France

Tarun K. Garg, PhD, Ricky D Edmondson, Ph.D.^*, Shweta S. Chavan, PhD^*, Katie Stone, BS^*, Justin M Stivers^*, Jessica I Warden^*, Veronica Macleod^*, Charles M Skinner^*, Joshuah D Lingo^*, Amy D Greenway^*, Junaid Khan^*, Donald Johann, MD, MS, Christoph Heuck, MD, Bart Barlogie, MD, PhD, Gareth J Morgan, MD PhD, Joshua Epstein, DSc and Frits van Rhee, MD, PhD

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Peter A. Forsberg, MD¹, Tomer M Mark, MD, MSc², Sujitha Yadlapati, MBBS^1*, Adriana C Rossi, MD, MHS², Roger N Pearse, MD, PhD^2*, Karen Pekle, NP^1*, Arthur Perry, PA^1*, Morton Coleman, MD¹, David Jayabalan, BSMS, MSc^2*, Ruben Niesvizky, MD² and Scott Ely, MD, MPH³

¹Division of Hematology / Oncology, Weill Cornell Medical College, New York, NY
²Center of Excellence for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY
³Department of Pathology, Weill Cornell Medical College, New York, NY

Janani Ramachandran, MA^1*, Loredana Santo, MD^1*, Homare Eda, MD, PhD^2*, Dharminder Chauhan, PhD³, Ka Tat Siu, PhD², Miroslav Koulnis, PhD^2*, Dennis Huszar, Ph.D.⁴, Kenneth C Anderson, MD⁵ and Noopur S. Raje, MD²

¹Massachusetts General Hospital, Boston, MA
²Massachusetts General Hospital Cancer Center, Boston, MA
³The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Oncology iMed, AstraZeneca, Waltham, MA
⁵LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Karen Curtin, PhD^1,2*, Yi Zhao, MS^1*, Donglei Hu, PhD^3*, Guido J Tricot, MD, PhD⁴, Elad Ziv, MD^3*, Djordje Atanackovic, MD^2,5 and Nicola J Camp, PhD^2,5*

¹Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
²Huntsman Cancer Institute, Salt Lake City, UT
³Medicine, Institute for Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
⁴Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
⁵Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, UT

Irtisha Singh^1,2*, Mehmet K Samur, Ph.D^3,4*, Lee Shih-Han^5*, Adam Samuel Sperling, MD, PhD⁶, Yu-Tzu Tai, PhD⁷, Mariateresa Fulciniti⁸, Christina S Leslie, PhD^1*, Christine Mayr^5* and Nikhil C. Munshi, MD⁴

¹Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY
²Tri-Institutional Training Program in Computational Biology and Medicine, New York, NY
³Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
⁴LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Dana-Farber Cancer Institute, Boston, MA
⁷Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Haiming Chen, MD, PhD, Mingjie Li, BS^*, Eric Sanchez, BA^*, Abigail Gillespie, BS^*, Cathy Wang, BS^*, Tiffany Lee^*, Suzie Vardanyan, MS^*, Jason Nosrati, BS^*, Jasmin Cao^*, Michael Zahab^*, Puja Mehta, BS^*, George Tang, PhD^* and James Berenson, MD

Institute for Myeloma & Bone Cancer Research, West Hollywood, CA

Tobias Meissner^1*, Anja Seckinger, MD^2*, Kari Hemminki, PhD^3*, Uta Bertsch, MD^4*, Asta Foersti^5*, Mathias Haenel, MD^6*, Jan Duering^7*, Hans-Juergen Salwender, MD^8*, Hartmut Goldschmidt, MD⁹, Gareth J Morgan, MD PhD¹⁰, Dirk Hose, MD¹¹ and Niels Weinhold, PhD^10*

¹Department of Molecular and Experimental Medicine, Avera Cancer Institute, La Jolla, CA
²Dept of Internal Medicine, Hematology & Oncology, Heidelberg University Hospital, Heidelberg, Germany
³German Cancer Research Centre, Heidelberg, Germany
⁴Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁵Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁶Klinikum Chemnitz, Chemnitz, Germany
⁷Dept of Hematology, University Hospital Essen, Essen, Germany
⁸Asklepios Hospital Hamburg Altona, Hamburg, Germany
⁹Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany
¹⁰Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
¹¹Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany

Subodh Kumar, PhD^1,2*, Srikanth Talluri, PhD^1,3*, Mariateresa Fulciniti¹, Masood A Shammas, PhD^1,2 and Nikhil C. Munshi, MD^2,4

¹The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²VA Boston Healthcare System, West Roxbury, MA
³VA Boston Healthcare System, west roxbury, MA
⁴Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA